CTLA4 and melanoma: Indeed, melanoma patients responding to anti-CTLA-4 therapy (ipilimumab, hIgG1) displayed increased levels of circulating nonclassical FcγRIIIa-expressing monocytes able to lyse Tregs ex vivo, and additionally showed a decrease in intra-tumoral Tregs after treatment with concurrent presence of FcγRIIIa-expressing M1-like macrophages in the tumor (41).